Marathon Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Marathon Capital Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$464K	Buy	151,295 +6,700	+5%	+$25.9K	0.1%	110
2025 Q4	$591K	Buy	144,595 +4,600	+3%	+$22.8K	0.13%	97
2025 Q3	$683K	Sell	139,995 -1,900	-1%	-$9.98K	0.16%	86
2025 Q2	$718K	Sell	141,895 -7,950	-5%	-$39.1K	0.18%	78
2025 Q1	$793K	Buy	149,845 +3,450	+2%	+$25.2K	0.21%	69
2024 Q4	$990K	Sell	146,395 -35,450	-19%	-$238K	0.25%	68
2024 Q3	$1.2M	Buy	181,845 +6,625	+4%	+$47.5K	0.29%	62
2024 Q2	$1.31M	Buy	175,220 +2,675	+2%	+$23.3K	0.33%	60
2024 Q1	$1.72M	Buy	172,545 +7,665	+5%	+$85.4K	0.41%	54
2023 Q4	$1.63M	Sell	164,880 -5,735	-3%	-$40.9K	0.41%	60
2023 Q3	$1.31M	Buy	+170,615	New	+$1.7M	0.33%	65

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Marathon Capital Management's RXRX Position: Q1 2026 in Review

Marathon Capital Management increased its Recursion Pharmaceuticals (RXRX) stake by 4.6% in Q1 2026, buying an estimated $25.9K and bringing the position to 151,295 shares worth $464K. The position accounts for 0.1% of the portfolio, ranked #110.

Marathon Capital Management first reported a position in RXRX in Q3 2023 and has held it in 11 quarters since. The position peaked at $1.72M in Q1 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Marathon Capital Management held 151,295 shares of Recursion Pharmaceuticals worth $464K as of Q1 2026.
Marathon Capital Management bought 6,700 Recursion Pharmaceuticals shares in Q1 2026, an estimated $25.9K.
Recursion Pharmaceuticals made up 0.1% of Marathon Capital Management's portfolio in Q1 2026, its #110 holding.
Marathon Capital Management first reported a position in Recursion Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
Marathon Capital Management's Recursion Pharmaceuticals position peaked at $1.72M in Q1 2024.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Marathon Capital Management's 13F filing for Q1 2026, filed 14 May 2026.